Pharmaceutical Product Development (PPD) and the Charité–Universitätsmedizin Berlin have formed a new collaboration between the company and the hospital’s clinical trials management unit (CTMU) to increase the volume of clinical trials conducted in Germany, improve access to commercial clinical research for patients, accelerate the development of new medicines and enhance health care treatment opportunities for German citizens.
The collaboration builds upon the long-standing relationship between PPD and the Charité. With 13,200 employees, the hospital maintains more than 100 clinics and institutes within 17 CharitéCenters at its four campuses.
“Germany’s abundance of intellectual and technical resources, coupled with the ongoing advances that have streamlined the clinical research process, make the country extremely attractive for clinical research,” said Roger Newbery, PPD’s vice president of clinical management for Europe, Middle East and Africa.
PPD will collaborate with the CTMU to shorten study start-up times, maximize the number of patients recruited for clinical trials, generate continued high-quality data and ensure all site staff members are trained as necessary for the conduct of clinical studies.
“By extending our relationship with PPD, our aim is to ensure improved access to novel medicines and advance our mission of securing lasting health improvements for our patients,” said Gerrit Fleige, executive director, finance and administration of the medical faculty of the Charité–Universitätsmedizin Berlin.
The agreement includes a wide range of phase I-IV trials across multiple therapeutic areas.